Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Core Insights - The webinar focuses on the 2-year readout from Evaxion's Phase II study in advanced melanoma, highlighting the significance of the results and their implications for high-risk melanoma treatment [1][2]. Group 1: Company Overview - Evaxion is introducing its AI-Immunology platform, which is central to its research and development efforts in advanced melanoma [2]. Group 2: Study Details - The agenda includes an introduction to Evaxion, a review of data from the Phase I study that led to the Phase II study, and a detailed presentation of the Phase II study design and results by Professor Khattak [2]. - The Phase II study results are expected to provide insights into the effectiveness of the treatment for high-risk melanoma patients [1][2]. Group 3: Engagement and Interaction - The webinar encourages audience participation through a question-and-answer session, allowing attendees to engage directly with the presenters [2].